Project Grant R21HL181171
- The University of Southern California (USC) was awarded a $808,121 Project Grant by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The project aims to elucidate how lymphatic endothelial cells detect external fluid forces and convert these signals into a biological program that orchestrates lymphatic valve formation. Specifically, the research will examine the role of the mechanosensitive ion channel PIEZO1 in sensing...
- This $147,486 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at the University of Southern California to investigate the heterogeneous intercellular signaling of hematopoietic stem and progenitor cells (HSPCs) and its changes around the circadian clock. The research aims to advance understanding of how HSPC cell-cell communication and gene expression patterns within the bone marrow microenvironment are...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $156,486 to Emory University to evaluate how immigration status contributes to disparities in cardiometabolic health and epigenetic aging among Hispanic/Latino populations in the U.S. The research leverages data from the California Health Interview Survey and the Hispanic Community Health Study/Study of Latinos to investigate the associations between...
- This federal Project Grant award for $637,913, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research by the University of Southern California (USC) to investigate the role of "transitional alveolar epithelial cells" in lung development and regeneration. The goal is to better understand the mechanisms underlying the alveolar epithelial cell differentiation process during normal lung development, as...
- The University of Southern California (USC) was awarded a $442,404 Project Grant (Federal Grant Award ID: R21CA274416) by the National Cancer Institute (NCI), under the NCI's "Cancer Cause and Prevention Research" program (CFDA 93.393). This funding supports a research project titled "Mitochondrial Dysfunction Underlies Treatment Related Hepatotoxicity in Hispanics with Acute Lymphoblastic Leukemia." The project aims to identify the underlying causes of treatment-related...
- The National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $147,486 project grant to Baylor College of Medicine to study the genetics of cardiovascular disease (CVD) across diverse and mixed-ancestry populations. The goal is to improve genetic testing for CVD and lipoprotein A, a lipoprotein that increases CVD risk, by evaluating the role of linkage disequilibrium and genetic structure. This ancestry-informed approach aims...
- This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $413,300.00 to the University of Southern California (USC) to conduct research in three critical areas of human genetics. The funded research will: Model recessive selection on complex traits by leveraging X chromosome data to better understand the strength of selection across different traits and diseases. Explore...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $790,498 to the University of Southern California (USC) for a research project entitled "Targeting PCBP1 to Ameliorate Pathological Angiogenesis". The grant, which runs from September 1, 2025 to June 30, 2030, aims to investigate the role of the PCBP1 protein and its target AARS2 in regulating vascular endothelial growth factor (VEGF) signaling and...
- This $802,762 federal Project Grant was awarded on February 1, 2025 by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to The University of Texas Southwestern Medical Center in Dallas, TX. The grant supports research to interpret the impact of genetic variants, both coding and non-coding, on the development of congenital heart disease (CHD) by defining cardiac gene regulatory networks. The research aims to characterize the functions of variants in...
- The National Heart Lung and Blood Institute awarded a $719,882 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF) to elucidate lung-specific immune pathways driving post-hematopoietic cell transplant lung injury in children. The research aims to identify cellular and molecular targets for precision diagnostics and therapeutics. Specifically, the project will leverage bronchoalveolar lavage fluid...
The University of Southern California (USC) was awarded a $262,159 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) on September 10, 2025. The grant supports a research project to understand the genetic regulation of gene expression in umbilical cord blood samples from Hispanic/Latino newborns. The objectives are to identify expression quantitative trait loci (eQTLs) and use transcriptome-wide association studies (TWAS) to discover genetic effects on early-life and adult-onset traits in this population. The project aims to address the paucity of data on gene expression in Hispanic/Latino newborns, which may impact the discovery of genetic-disease associations relevant to this community. The research will leverage the NHLBI's BIOLINCC biorepository to generate new mRNA sequencing and genome-wide SNP data from 400 Hispanic/Latino cord blood samples, with the goal of improving the understanding of the genetic architecture of early-life gene expression and its implications for health disparities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $262.2k | 9/10/25 |